Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Foghorn Therapeutics Inc. (FHTX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities – Foghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader program – Company to focus resources on wholly owned pipeline, including a Se
How this was made
The 30-second read
Why it matters
Shares are expected to react negatively on the day of the filing due to loss of a late‑stage asset and significant layoff news.
Market read
The announcement directly affects FHTX valuation and may influence peer biotech stocks focused on similar targets.
What to watch
Potential for strategic partnerships on the remaining EP300 and CBP programs could mitigate the loss of the SMARCA2 asset.
Background
The 8‑K filing is the first public disclosure of the program termination and restructuring plan.
Ticker impact
Foghorn Therapeutics announced it will not advance the FHD-909 SMARCA2 program and will cut ~40% of its workforce, extending cash runway to 2029.
downward pressure as investors reassess valuation without the SMARCA2 program
Program cancellation removes a potential revenue source; workforce cuts signal cost‑saving but also raise concerns about execution capability.
Market effects
Biotech sector may see modest sell‑off in epigenetic‑target firms as pipeline risk perception rises.
US biotech investors likely to adjust exposure; limited impact outside the sector.
Minimal global effect beyond niche oncology/epigenetics investors.
Counterpoint
The workforce reduction could extend cash runway, allowing focus on higher‑potential proprietary programs, potentially supporting a longer‑term upside.
Key entities
- companyFoghorn Therapeutics Inc.
Biotech firm developing epigenetic degrader therapies.
- partnerEli Lilly and Company
Co‑developer of the discontinued FHD‑909 program.